Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS)
CNY 220.76
(0.79%)
CNY 220.76
(0.79%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.14 Billion CNY | 13.03% |
| 2022 | 2.77 Billion CNY | 17.86% |
| 2021 | 2.35 Billion CNY | 21.01% |
| 2020 | 1.94 Billion CNY | 5.86% |
| 2019 | 1.84 Billion CNY | 36.36% |
| 2018 | 1.35 Billion CNY | 10.39% |
| 2017 | 1.22 Billion CNY | -4.97% |
| 2016 | 1.28 Billion CNY | 71.24% |
| 2015 | 751.59 Million CNY | 13.48% |
| 2014 | 662.33 Million CNY | -0.71% |
| 2013 | 667.05 Million CNY | -1.21% |
| 2012 | 675.22 Million CNY | 77.83% |
| 2011 | 379.69 Million CNY | 4.61% |
| 2010 | 362.96 Million CNY | -15.07% |
| 2009 | 427.35 Million CNY | 34.2% |
| 2008 | 318.44 Million CNY | 50.19% |
| 2007 | 212.02 Million CNY | 93.59% |
| 2006 | 109.52 Million CNY | 28.01% |
| 2005 | 85.55 Million CNY | 334.47% |
| 2004 | 19.69 Million CNY | -52.44% |
| 2003 | 41.4 Million CNY | -75.79% |
| 2002 | 170.98 Million CNY | 37.51% |
| 2001 | 124.34 Million CNY | 5.98% |
| 2000 | 117.32 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.38 Billion CNY | 7.83% |
| 2024 Q2 | 2.78 Billion CNY | -17.95% |
| 2024 Q3 | 3.38 Billion CNY | 21.79% |
| 2023 FY | 3.14 Billion CNY | 13.03% |
| 2023 Q3 | 2.53 Billion CNY | -21.7% |
| 2023 Q4 | 3.14 Billion CNY | 23.89% |
| 2023 Q1 | 2.43 Billion CNY | -12.35% |
| 2023 Q2 | 3.23 Billion CNY | 32.94% |
| 2022 Q3 | 2.13 Billion CNY | -25.38% |
| 2022 Q4 | 2.77 Billion CNY | 30.28% |
| 2022 FY | 2.77 Billion CNY | 17.86% |
| 2022 Q1 | 2.09 Billion CNY | -11.17% |
| 2022 Q2 | 2.85 Billion CNY | 36.48% |
| 2021 Q2 | 2.05 Billion CNY | -2.29% |
| 2021 Q1 | 2.1 Billion CNY | 7.83% |
| 2021 FY | 2.35 Billion CNY | 21.01% |
| 2021 Q4 | 2.35 Billion CNY | 8.03% |
| 2021 Q3 | 2.18 Billion CNY | 6.32% |
| 2020 Q1 | 1.77 Billion CNY | -3.33% |
| 2020 FY | 1.94 Billion CNY | 5.86% |
| 2020 Q2 | 1.66 Billion CNY | -6.43% |
| 2020 Q4 | 1.94 Billion CNY | -11.34% |
| 2020 Q3 | 2.19 Billion CNY | 32.01% |
| 2019 Q1 | 1.55 Billion CNY | 15.39% |
| 2019 Q3 | 1.82 Billion CNY | 5.71% |
| 2019 Q4 | 1.84 Billion CNY | 0.73% |
| 2019 FY | 1.84 Billion CNY | 36.36% |
| 2019 Q2 | 1.72 Billion CNY | 10.96% |
| 2018 Q4 | 1.35 Billion CNY | -6.24% |
| 2018 Q3 | 1.43 Billion CNY | 3.21% |
| 2018 Q2 | 1.39 Billion CNY | 3.27% |
| 2018 Q1 | 1.35 Billion CNY | 10.46% |
| 2018 FY | 1.35 Billion CNY | 10.39% |
| 2017 Q4 | 1.22 Billion CNY | 1.01% |
| 2017 Q2 | 984.2 Million CNY | -8.23% |
| 2017 Q1 | 1.07 Billion CNY | -16.67% |
| 2017 FY | 1.22 Billion CNY | -4.97% |
| 2017 Q3 | 1.21 Billion CNY | 23.03% |
| 2016 Q4 | 1.28 Billion CNY | 22.05% |
| 2016 Q3 | 1.05 Billion CNY | 25.25% |
| 2016 FY | 1.28 Billion CNY | 71.24% |
| 2016 Q2 | 841.95 Million CNY | 1.47% |
| 2016 Q1 | 829.73 Million CNY | 10.4% |
| 2015 Q1 | 628.43 Million CNY | -5.12% |
| 2015 FY | 751.59 Million CNY | 13.48% |
| 2015 Q2 | 656.18 Million CNY | 4.42% |
| 2015 Q4 | 751.59 Million CNY | 10.11% |
| 2015 Q3 | 682.58 Million CNY | 4.02% |
| 2014 Q2 | 605.21 Million CNY | -8.14% |
| 2014 FY | 662.33 Million CNY | -0.71% |
| 2014 Q1 | 658.87 Million CNY | -1.23% |
| 2014 Q4 | 662.33 Million CNY | 3.82% |
| 2014 Q3 | 637.98 Million CNY | 5.42% |
| 2013 Q1 | 701.69 Million CNY | 3.92% |
| 2013 Q2 | 730.23 Million CNY | 4.07% |
| 2013 Q3 | 693.07 Million CNY | -5.09% |
| 2013 FY | 667.05 Million CNY | -1.21% |
| 2013 Q4 | 667.05 Million CNY | -3.75% |
| 2012 FY | 675.22 Million CNY | 77.83% |
| 2012 Q3 | 683.08 Million CNY | 10.54% |
| 2012 Q2 | 617.97 Million CNY | -7.04% |
| 2012 Q1 | 664.78 Million CNY | 75.08% |
| 2012 Q4 | 675.22 Million CNY | -1.15% |
| 2011 FY | 379.69 Million CNY | 4.61% |
| 2011 Q4 | 379.69 Million CNY | -4.36% |
| 2011 Q1 | 385.48 Million CNY | 6.2% |
| 2011 Q2 | 414.3 Million CNY | 7.47% |
| 2011 Q3 | 397.01 Million CNY | -4.17% |
| 2010 Q3 | 388.86 Million CNY | -1.8% |
| 2010 FY | 362.96 Million CNY | -15.07% |
| 2010 Q4 | 362.96 Million CNY | -6.66% |
| 2010 Q1 | 450.54 Million CNY | 5.43% |
| 2010 Q2 | 396 Million CNY | -12.1% |
| 2009 FY | 427.35 Million CNY | 34.2% |
| 2009 Q1 | 320.78 Million CNY | 0.73% |
| 2009 Q2 | 374.78 Million CNY | 16.83% |
| 2009 Q3 | 393.81 Million CNY | 5.08% |
| 2009 Q4 | 427.35 Million CNY | 8.52% |
| 2008 FY | 318.44 Million CNY | 50.19% |
| 2008 Q1 | 214.02 Million CNY | 0.95% |
| 2008 Q2 | 270.93 Million CNY | 26.59% |
| 2008 Q4 | 318.44 Million CNY | 4.97% |
| 2008 Q3 | 303.37 Million CNY | 11.97% |
| 2007 Q4 | 212.02 Million CNY | 18.99% |
| 2007 Q3 | 178.19 Million CNY | 1.88% |
| 2007 Q2 | 174.9 Million CNY | 72.53% |
| 2007 Q1 | 101.37 Million CNY | -7.44% |
| 2007 FY | 212.02 Million CNY | 93.59% |
| 2006 Q2 | 98.65 Million CNY | 2.46% |
| 2006 Q3 | 97.77 Million CNY | -0.89% |
| 2006 Q4 | 109.52 Million CNY | 12.02% |
| 2006 FY | 109.52 Million CNY | 28.01% |
| 2006 Q1 | 96.28 Million CNY | 12.54% |
| 2005 Q3 | 113.33 Million CNY | 9.43% |
| 2005 Q2 | 103.57 Million CNY | 840.92% |
| 2005 Q1 | 11 Million CNY | -44.1% |
| 2005 FY | 85.55 Million CNY | 334.47% |
| 2005 Q4 | 85.55 Million CNY | -24.51% |
| 2004 Q3 | 32.63 Million CNY | -0.65% |
| 2004 Q1 | 28.31 Million CNY | -31.61% |
| 2004 Q2 | 32.84 Million CNY | 16.01% |
| 2004 FY | 19.69 Million CNY | -52.44% |
| 2004 Q4 | 19.69 Million CNY | -39.66% |
| 2003 Q3 | 25.15 Million CNY | -66.2% |
| 2003 Q2 | 74.41 Million CNY | 0.0% |
| 2003 FY | 41.4 Million CNY | -75.79% |
| 2003 Q4 | 41.4 Million CNY | 64.59% |
| 2002 Q4 | 170.98 Million CNY | 0.0% |
| 2002 FY | 170.98 Million CNY | 37.51% |
| 2001 FY | 124.34 Million CNY | 5.98% |
| 2000 FY | 117.32 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Jiangsu Hengrui Medicine Co., Ltd. | 2.75 Billion CNY | -14.205% |
| Zhejiang CONBA Pharmaceutical Co.,Ltd. | 3.88 Billion CNY | 19.193% |
| Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. | 887.5 Million CNY | -254.052% |
| Aurora Optoelectronics Co.,Ltd. | 1.09 Billion CNY | -185.71% |
| Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd | 290.34 Million CNY | -982.265% |
| NanJing Pharmaceutical Company Limited | 20.95 Billion CNY | 85.007% |
| GuangYuYuan Chinese Herbal Medicine Co., Ltd. | 1.12 Billion CNY | -180.42% |
| Tonghua Dongbao Pharmaceutical Co., Ltd. | 527.57 Million CNY | -495.604% |